Topica Pharmaceuticals Inc

Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company located in Los Altos, California. Employing 20-49 individuals, the company focuses on the clinical development of luliconazole for onychomycosis. Topica Pharmaceuticals specializes in developing treatments for onychomycosis, commonly known as nail fungus. Onychomycosis affects millions of patients in the United States, yet treatment rates remain low due to limitations of existing FDA-approved medications. Topica holds exclusive rights to luliconazole in North America and Europe, leveraging its efficacy as a leading topical prescription antifungal in Japan. Luliconazole stands out as the most potent antifungal molecule known against common fungal pathogens causing nail fungus. Its potency surpasses the most potent currently approved treatment, oral terbinafine, by approximately 60 times. Topica's 10% Luliconazole Solution is currently undergoing a phase 2b/3 trial, with results anticipated in the third quarter of 2014. For further information, please visit Topica Pharmaceuticals' website at topicapharma.com.